DISCUSSION
nonsquamous NSCLC
ADVERSE EVENTS
It is well‐known that immunotherapy in Despite the negative impact of However, this phase 2 study failed to show any improvement in outcomes compared with previous studies on second‐line cytotoxic chemotherapy following EGFR‐TKI. In an open‐label phase 3 study called CheckMate‐057, patients with nonsquamous NSCLC that had progressed during or after platinum‐based doublet chemotherapy received nivolumab. The study reported a median PFS of 2.3 months and a median OS of 12.2 months.Some studies have suggested that a high TMB may predict a good clinical response in the treatment with immune check point inhibitors.The safety profile of nivolumab in this study was consistent with that in previous studies.There has been ongoing research focused on evaluating the efficacy of combining immunotherapy with chemotherapy in In conclusion, nivolumab maintenance following platinum‐based chemotherapy was well‐tolerated and showed no new unexpected adverse events. However, it failed to show clinical benefits after EGFR‐TKI failure in patients with 